文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肛周克罗恩病的流行病学和自然史:基于人群队列的系统评价和荟萃分析。

Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.

机构信息

Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Division of Gastroenterology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

出版信息

Inflamm Bowel Dis. 2022 Oct 3;28(10):1477-1484. doi: 10.1093/ibd/izab287.


DOI:10.1093/ibd/izab287
PMID:34792604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9527611/
Abstract

BACKGROUND AND AIMS: Perianal Crohn's disease (pCD) is a potentially severe phenotype of CD. We conducted a systematic review with meta-analysis to estimate cumulative incidence, risk factors, and outcomes of pCD in population-based cohort studies. METHODS: Through a systematic literature review through March 1, 2021, we identified population-based inception cohort studies reporting cumulative incidence of perianal disease (primarily abscess and/or fistula) in patients with CD. We estimated the cumulative incidence of pCD at presentation and 1-, 5-, and 10-year follow-up, and risk factors for perianal disease and outcomes including risk of major (bowel resection, proctectomy, ostomy) and minor perianal (incision and drainage, seton placement, etc.) surgery. RESULTS: In 12 population-based studies, prevalence of pCD was 18.7% (95% confidence interval [CI], 12.5%-27.0%) with 1-, 5-, and 10-year risk of perianal disease being 14.3% (95% CI, 7.9%-24.6%), 17.6% (95% CI, 11.3%-26.5%), and 18.9% (95% CI, 15.0%-23.4%), respectively. Approximately 11.5% of patients (95% CI, 6.7%-19.0%) had perianal disease at or before CD diagnosis. Colonic disease location and rectal involvement were associated with higher risk of pCD. Overall, 63.3% of patients (95% CI, 53.3-72.3) required minor perianal surgery and 6.4% of patients (95% CI, 1.8%-20.6%) required major abdominal surgery for pCD. Use of biologic therapy for pCD is common and has steadily increased throughout the years. CONCLUSIONS: Approximately 1 in 5 patients with CD develops perianal disease within 10 years of CD diagnosis, including 11.5% who have perianal disease at presentation. Approximately two-thirds of patients require perianal surgery, with a smaller fraction requiring major abdominal surgery.

摘要

背景与目的:肛周克罗恩病(pCD)是一种潜在严重的克罗恩病表型。我们进行了一项系统综述和荟萃分析,以估计人群队列研究中 pCD 的累积发病率、危险因素和结局。

方法:通过系统文献综述,我们在 2021 年 3 月 1 日之前确定了报告 CD 患者肛周疾病(主要为脓肿和/或瘘管)累积发病率的基于人群的起始队列研究。我们估计了 pCD 在就诊时以及 1、5 和 10 年随访时的累积发病率,以及肛周疾病的危险因素和结局,包括主要(肠切除术、直肠切除术、造口术)和次要(切开引流术、挂线术等)肛周手术的风险。

结果:在 12 项基于人群的研究中,pCD 的患病率为 18.7%(95%置信区间[CI],12.5%-27.0%),1、5 和 10 年肛周疾病的风险分别为 14.3%(95%CI,7.9%-24.6%)、17.6%(95%CI,11.3%-26.5%)和 18.9%(95%CI,15.0%-23.4%)。约 11.5%的患者(95%CI,6.7%-19.0%)在 CD 诊断时或之前就有肛周疾病。结肠疾病位置和直肠受累与 pCD 的高风险相关。总体而言,63.3%的患者(95%CI,53.3%-72.3%)需要接受次要肛周手术,6.4%的患者(95%CI,1.8%-20.6%)需要接受主要腹部手术治疗 pCD。生物治疗在 pCD 中的应用很常见,并且多年来一直在稳步增加。

结论:约 1/5 的 CD 患者在 CD 诊断后 10 年内会发生肛周疾病,其中 11.5%在就诊时就有肛周疾病。约 2/3 的患者需要接受肛周手术,其中较小比例的患者需要接受主要腹部手术。

相似文献

[1]
Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.

Inflamm Bowel Dis. 2022-10-3

[2]
Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn's Disease: A Nationwide Population-Based Study.

Dig Dis Sci. 2020-4

[3]
Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort.

Inflamm Bowel Dis. 2019-5-4

[4]
Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study.

J Crohns Colitis. 2018-11-28

[5]
Natural History of Perianal Crohn's Disease: Long-term Follow-up of a Population-Based Cohort.

Clin Gastroenterol Hepatol. 2022-2

[6]
Clinical outcomes and long-term prognosis of perianal Crohn's disease in an Asian population.

J Gastroenterol Hepatol. 2021-6

[7]
Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.

Clin Gastroenterol Hepatol. 2013-1-30

[8]
Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort.

Clin Gastroenterol Hepatol. 2022-3

[9]
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.

J Crohns Colitis. 2024-1-27

[10]
Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.

Colorectal Dis. 2016-7

引用本文的文献

[1]
Analysis of risk factors for postoperative bleeding in anal surgery: A retrospective cohort study.

Medicine (Baltimore). 2025-8-8

[2]
Long-term effectiveness of allogeneic bone marrow-derived mesenchymal stromal cell therapy for complex perianal and rectovaginal fistulas in Crohn's disease: a retrospective case series.

BMJ Open Gastroenterol. 2025-8-4

[3]
Epidemiology, treatment patterns, and associated risk factors in perianal fistulizing Crohn's disease: A systematic literature review.

World J Gastrointest Surg. 2025-7-27

[4]
Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.

Gastro Hep Adv. 2025-5-9

[5]
Treatment of perianal abscess and anal fistula in infants: a systematic review.

Front Surg. 2025-6-13

[6]
A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease.

Curr Gastroenterol Rep. 2025-6-27

[7]
Clinical trials and young adults with inflammatory bowel disease.

Health Care Transit. 2025-3-31

[8]
Current practice and innovations in diagnosing perianal fistulizing Crohn's disease (pfCD): a narrative review.

Tech Coloproctol. 2025-4-15

[9]
Patients' Attitudes to Magnetic Resonance Imaging in Perianal Fistulizing Crohn's Disease: A Global Survey.

Crohns Colitis 360. 2025-3-12

[10]
The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Multicentre Study.

Aliment Pharmacol Ther. 2025-5

本文引用的文献

[1]
AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Gastroenterology. 2021-6

[2]
AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Gastroenterology. 2021-6

[3]
Fecal Diversion for Perianal Crohn Disease in the Era of Biologic Therapies: A Multicenter Study.

Inflamm Bowel Dis. 2022-2-1

[4]
Fistulizing perianal lesions in a French population with Crohn's disease.

Dig Liver Dis. 2021-5

[5]
Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.

J Crohns Colitis. 2021-8-2

[6]
Natural History of Perianal Crohn's Disease: Long-term Follow-up of a Population-Based Cohort.

Clin Gastroenterol Hepatol. 2022-2

[7]
Burden of disease and adaptation to life in patients with Crohn's perianal fistula: a qualitative exploration.

Health Qual Life Outcomes. 2020-11-20

[8]
Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts.

Clin Gastroenterol Hepatol. 2021-10

[9]
The Incidence and Disease Course of Perianal Crohn's Disease: A Danish Nationwide Cohort Study, 1997-2015.

J Crohns Colitis. 2021-1-13

[10]
Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease.

JAMA Netw Open. 2020-6-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索